Official title: Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease Summary: This multisite prospective study seeks to determine if HLA-identical sibling donor transplantation using alemtuzumab, low dose total-body irradiation, and sirolimus (Sickle transplant Using a Nonmyeloablative approach, "SUN") can decrease the toxicity of transplant while achieving a high cure rate for children with sickle cell disease (SCD). Conditions: Sickle Cell Disease Study type: INTERVENTIONAL Primary purpose: TREATMENT Phases: PHASE2 Enrollment: 100 (ESTIMATED) Status: RECRUITING Completion: 2030-11 (ESTIMATED)
ClinicalTrials.gov published a clinical update in Infectious Disease on 10 Mar 2026.
The item focuses on Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease.
Review the original article for the full source wording and details.